

1

2 **Cryoprotectant agent toxicity in porcine articular chondrocytes**

3

4 Nadr M. Jomha MD, PhD<sup>1</sup>, Andrew D.H. Weiss MSc<sup>1</sup>, J. Fraser Forbes PhD<sup>2</sup>, Garson K.  
5 Law MSc<sup>1</sup>, Janet A.W. Elliott PhD<sup>2</sup>, Locksley E. McGann PhD<sup>3</sup>

6

7 <sup>1</sup> Department of Surgery, University of Alberta, Edmonton Canada

8 <sup>2</sup> Department of Chemical and Materials Engineering, University of Alberta, Edmonton  
9 Canada

10 <sup>3</sup> Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton  
11 Canada

12

13 Corresponding Author:

14 Nadr Jomha

15 2D2.32 WMC Department of Surgery

16 University of Alberta Hospital

17 Edmonton, Alberta

18 Canada T6G 2B7

19 Ph: 1 780 407 2816

20 Fax: 1 780 407 2819

21 Email: [njomha@ualberta.ca](mailto:njomha@ualberta.ca)

22

NOTICE: this is the author's version of a work that was accepted for publication in *Cryobiology*. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in *Cryobiology*, Volume 61, Issue 3, December 2010, Pages 297-302. <http://dx.doi.org/10.1016/j.cryobiol.2010.10.002>.

23 **Abstract**

24

25 Large articular cartilage defects have proven difficult to treat and often result in  
26 osteoarthritis of the affected joint. Cryopreservation of articular cartilage can provide an  
27 increased supply of tissues for osteochondral allograft but cryoprotective agents are  
28 required; however, few studies have been performed on the toxicity of these agents. This  
29 study was designed to determine the order of toxicity of five commonly used  
30 cryoprotectant agents as well as interactions that occur between them. Isolated porcine  
31 articular chondrocytes were exposed to individual cryoprotectant agents and  
32 combinations of these agents at 1M and 3M concentrations for 5 minutes and 120  
33 minutes. Cell viability was determined using membrane integrity dyes and a metabolic  
34 activity assay. Subsequently, a regression analysis based study was undertaken to extract  
35 the maximum amount of information from this data. Results of this study demonstrated  
36 that all 1M solutions were minimally toxic. The 3M solutions demonstrated varying  
37 toxicity after 120 minutes. Ethylene glycol and glycerol were less toxic than propylene  
38 glycol, dimethyl sulfoxide, and formamide. Combinations of cryoprotectant agents were  
39 less toxic than single cryoprotectant agents at the same concentration. This is the most  
40 comprehensive study investigating cryoprotectant agent toxicity in articular chondrocytes  
41 and has resulted in important information regarding the order of toxicity and interactions  
42 that occur between these agents.

43

44 **Key Words**

45 Articular cartilage, cryoprotectant agents, viability, statistical analysis, porcine,  
46 chondrocytes, cryopreservation

47

48 **Introduction**

49 Treatment techniques for articular cartilage (AC) defects continue to be investigated.  
50 Despite these efforts, large defects confound clinicians because of the inability to  
51 reproduce the complex matrix using tissue engineering modalities. Historically, treatment  
52 of large defects, including whole joints has been accomplished using fresh osteochondral  
53 allografts[1; 2]. This technically demanding procedure is made more difficult because of  
54 logistical issues that require transplantation to occur within 48-72 hours of harvest. These  
55 issues include timing of the surgical procedure (i.e. obtaining a donor at the time a patient  
56 requires the graft), size and contour matching on short notice, having the appropriate  
57 surgical team available for the transplantation procedure, and possibility of transmission  
58 of infectious diseases. To accommodate for some of these obstacles, hypothermic storage  
59 of allografts at 4°C has been attempted. Unfortunately, recent studies have demonstrated  
60 that the cells and matrix begin to deteriorate after 7-14 days in these conditions[3; 4; 5;  
61 6]. Furthermore, regulatory conditions in some countries such as the United States require  
62 at least 14 days before clearance of this tissue for clinical use. Longer term storage of this  
63 tissue in a frozen state results in cell death and matrix damage with outcomes of frozen-  
64 thawed graft transplantations deteriorating after only two to five years[7]. It is with this  
65 background that cryopreservation of AC with maintenance of cell viability and matrix  
66 integrity has been investigated.

67

68 Cryopreservation of AC has proven extremely difficult. Initial standard cryopreservation  
69 (low cryoprotectant agent (CPA) concentration) techniques such as stepped cooling  
70 following by controlled freezing have been uniformly unsuccessful in maintaining cell

71 viability to any significant extent[8; 9; 10]. Furthermore, the formation of ice within the  
72 matrix alters its integrity[11] and that may have long term consequences on the  
73 transplanted tissue. More recently, vitrification has been investigated as a method to  
74 maintain cell viability while avoiding the alterations in the matrix. Standard single CPA  
75 vitrification has had some success in thin AC[12] but this has not been extended to  
76 thicker AC that is required in the clinical scenario. Multiple-agent vitrification has also  
77 had moderate success[13; 14; 15; 16] but, again, extension to the clinical realm has not  
78 been achieved due to difficulties in scaling up protocols.

79

80 Two important obstacles to the successful vitrification of clinically relevant thickness AC  
81 include CPA toxicity and permeation. The high concentrations of CPAs required to  
82 vitrify AC at realistic cooling rates are toxic to chondrocytes within minutes[17].  
83 Interestingly, investigations into mechanisms of toxicity and the effects of high  
84 concentrations of CPAs (especially with respect to chondrocytes) are relatively few[15;  
85 18; 19; 20; 21; 22; 23; 24]. To complicate matters, experiments on different tissues or  
86 cells result in different ordering of toxicity. Various studies in Zebrafish ovarian  
87 follicles[25], Abalone embryos[26], zebrafish germ cells[27], vascular endothelial  
88 cells[28], shrimp embryo and larvae[29] and mouse morula[30] have demonstrated that  
89 CPA toxicity is variable within different cells and different species with one CPA being  
90 the most toxic in one study but the least toxic in others. Fahy is one of the few  
91 investigators to attempt an evaluation of toxicity interactions between CPAs in AC[20].  
92 He concluded that it was possible to predict solution toxicity based on the number of  
93 moles of water per molar quantity of CPA polar groups in solution. One significant

94 drawback to this work was the limited number of combinations investigated but they  
95 were able to show some positive interactions between CPAs indicating that adding two  
96 CPAs together resulted in less toxicity than a prediction based on the addition of the  
97 effects of the two individual CPA toxicities. This study was recently expanded to include  
98 other possible positive interactions[24]. Zhang *et al.* performed a more comprehensive  
99 study in flounder that also showed positive interactions between different CPAs[31].

100

101 Given the toxic effects of high concentrations of CPA agents required for vitrification and  
102 the variability between cells and species, it is important to investigate the toxicity of  
103 CPAs alone and in combination with respect to articular chondrocytes if successful  
104 vitrification of AC is to be achieved. Furthermore, determination of positive and negative  
105 interactions of the commonly used CPAs will allow for informed decisions regarding the  
106 combination of these agents in multiple-agent vitrification solutions that are becoming  
107 more relevant. The main objective of this experiment was to determine the order of  
108 toxicity of five commonly used CPAs. A secondary objective was to determine any  
109 positive and negative interactions between pairs of these CPAs.

110

## 111 **Methods and Materials**

### 112 *Chondrocyte isolation*

113 Thin slices of AC were harvested from the weight-bearing region of porcine distal femurs  
114 donated by a local slaughterhouse (Sturgeon Valley Pork, St. Albert, AB) and immersed  
115 in a petri dish containing 1X phosphate-buffered saline (PBS, pH 7.1, Invitrogen,  
116 Carlsbad, CA). The cartilage slices were washed once with sterile 1X PBS. A 1 mg/mL

117 collagenase solution was prepared using solid collagenase (Sigma-Aldrich, St. Louis,  
118 MO) dissolved in Dulbecco's Modified Eagle Media (DMEM F-12, Invitrogen, Carlsbad,  
119 CA) containing 1 % penicillin/Streptomycin (Invitrogen, Carlsbad, CA) and 10% Fetal  
120 Bovine Serum (FBS, ATCC, Manassas, VA). The PBS was removed and the collagenase  
121 solution was filtered through a Millex GP .22 µm (PES) syringe filter (Millipore,  
122 Bedford, MA) onto the petri dish. The cartilage matrix was digested on top of a shaker  
123 for 6 hours at 37°C and 5% CO<sub>2</sub>. At the end of the digestion, the solution was filtered  
124 through a 40 µm cell strainer (Fisher Scientific, Waltham, MA) into a 50 mL centrifuge  
125 tube and centrifuged for 6 minutes at 400x g and 20°C (Eppendorf 5810 R, Eppendorf,  
126 Hamburg, DE) . The supernatant was removed, the pellet re-suspended in sterile 1x PBS  
127 and centrifuged again. The resultant supernatant was removed and the pellet was re-  
128 suspended in Dulbecco's Modified Eagle Media (DMEM F-12, Invitrogen, Carlsbad,  
129 CA) leaving chondrocytes without matrix. The cell density was determined using a  
130 Coulter Counter Z2 (Beckman Coulter, Fullerton, CA) and the chondrocytes were seeded  
131 at a concentration of 25,000 cells/100 µL in each well of a 96-well cell culture cluster  
132 (Corning, Corning, NY). The cluster was placed on a steady surface for 30 minutes at  
133 room temperature to allow the chondrocytes to attach to the bottom of the wells, and then  
134 incubated for 48 hours at 37°C and 5% CO<sub>2</sub>.

135

### 136 *Cryoprotectant solutions*

137 The cryoprotectant agents used included dimethyl sulphoxide (Me<sub>2</sub>SO), ethylene glycol  
138 (EG), propylene glycol (PG), glycerol (Gly) and formamide (Form). Using these agents,  
139 5 single-CPA aqueous solutions; 20 two-CPA solutions (10 combinations in 2 different

140 ratios); and 15 three-CPA solutions were formulated. For the single-CPA and three-CPA  
141 solutions, total concentrations of 1 and 3 M were used. For the two-CPA solutions, data  
142 were only collected at total solution concentrations of 3M.

143

144 Fifty microlitres of media was gently removed from the initial volume of 100  $\mu$ L using a  
145 sterile Vacurette 96 (Bel-Art, Pequannock, NJ) attached to a syringe. The wells were  
146 washed by adding and then removing 100  $\mu$ L of DMEM-F-12. The CPA solutions were  
147 added stepwise to avoid excessive intracellular volume changes. For the 1M treatment, 50  
148  $\mu$ L of a 2M CPA solution was added to each well to achieve the desired concentration.  
149 For the 3M treatment, 50  $\mu$ L of a 2M CPA solution was added; after 3 minutes 50  $\mu$ L was  
150 removed; 50  $\mu$ L of a 3M CPA solution was then added and removed after an additional 3  
151 minutes. Finally, 50  $\mu$ L of a 4M CPA solution was then added to achieve the desired  
152 concentration. For all treatments, the cell cluster was placed in an incubator at 37°C and  
153 5% CO<sub>2</sub> for either 5 or 120 minutes.

154

155 After the experimental treatment and incubation, the 3M CPA solutions were removed  
156 stepwise, again to avoid excessive changes in cell volume as follows. 33  $\mu$ L of the  
157 treatment solution was removed and replaced with an equal volume of DMEM-F12.  
158 After 3 minutes, 50  $\mu$ L was removed and replaced with an equal volume of DMEM-F12.  
159 For both 1M and 3M treatments, the wells were then washed twice with 100  $\mu$ L of  
160 DMEM-F12 to remove the remaining CPA.

161

162

163

164 *Cell Viability*

165 *Metabolic Activity*

166 Cell proliferation reagent was made by mixing WST-1 reagent (Roche, Basel, CH) in  
167 phenol red-free DMEM-F12 (5% penicillin/streptomycin, 10% FBS) at a concentration  
168 of 1  $\mu$ L/mL. The cell cluster wells were drained by inversion and 100  $\mu$ L of the cell  
169 proliferation solution was added to each well. The cell cluster was incubated at 37°C and  
170 5% CO<sub>2</sub> for 90 minutes. Following incubation, the absorbance was taken at 450 nm with  
171 a reference wavelength of 650 nm, using a SpectraMax Plus 384 spectrophotometer  
172 running SOFTmax PRO 5.3 software (Molecular Devices, Sunnyvale, CA).

173

174 *Membrane Integrity*

175 All excess DMEM-F12 solution was removed by inverting the well containing the cell  
176 cluster and chondrocyte nuclei were stained with 40  $\mu$ L of Syto13/Ethidium Bromide (8.6  
177  $\mu$ M/8.6  $\mu$ M in 1x PBS, Invitrogen, Carlsbad, CA / Sigma-Aldrich, St. Louis, MO). The  
178 cell cluster was incubated for 30 minutes at 20°C while protected from light and then  
179 imaged using a Nikon Eclipse TE 2000-U fluorescent microscope and NIS Elements  
180 software (v. F 2.30, Nikon, Tokyo, JP). Cell counts were determined using custom  
181 software (Viability 3.2.0.0, Cryolab, University of Alberta).

182

183 *Statistical Analysis*

184 In order to determine the primary toxicological effects of each cryoprotectant agent  
185 considered in this study and any interactions that arise from binary mixtures of these

186 CPAs, a regression analysis based study was undertaken. In particular, the data collected  
187 for the set of CPA mixtures described previously was used to estimate the parameters in a  
188 model of the form:

$$190 \quad y = \alpha + \sum_{i=1}^5 \beta_i x_i + \sum_{i=1}^5 \sum_{j=i+1}^5 \gamma_{ij} x_i x_j \quad (1)$$

191  
192 where  $y$  is the cell recovery expressed as a normalized fraction;  $\alpha$  represents cell  
193 recovery for a control solution containing no CPAs;  $x_i$  is the concentration (M) of the  $i^{\text{th}}$   
194 CPA;  $\beta_i$  is the coefficient for the primary effect of the  $i^{\text{th}}$  CPA; and  $\gamma_{ij}$  is the coefficient  
195 for the two factor interaction between the  $i^{\text{th}}$  and  $j^{\text{th}}$  CPAs.

196  
197 The regression studies were conducted sequentially starting with an investigation of the  
198 primary effects of the CPAs. In the second stage, the interactions between pairs of CPAs  
199 were investigated. In each study, linear least squares regression was used to estimate the  
200 set of coefficients in the appropriate regression model. Then, a hypothesis test of the  
201 form:

$$203 \quad H_0 : \{ \alpha, \beta_i, \gamma_{ij} \} = 0 \quad (2)$$

204  
205 was conducted (i.e. the estimated value for each coefficient was hypothesized to be  
206 indistinguishable from zero at a specified confidence level) at the 95% confidence level  
207 and using the estimated standard deviation for each coefficient estimate.

208

209 The results in Table 2 were produced using this regression analysis approach, using a  
210 modified version of Equation (1) where the interaction terms were omitted (i.e. was  
211 forced to be zero by truncating the equation after the second term). The results in Table 3  
212 were produced using the full regression model given in Equation (1).

213

214 Statistical analysis was performed using Matlab R2009b software (The MathWorks Inc.,  
215 Natick, MA).

216

## 217 **Results**

218 Cell viability was determined for single-CPA and three-CPA combinations at 1M and  
219 3M. This was done after 5 min and 120 min (Figures 1 and 2). For two-CPA  
220 combinations, only data at 3M was obtained (graph not shown). All 1M solutions were  
221 minimally toxic after 5 min and 120 min exposure to chondrocytes (Figure 1). The  
222 majority of 3M solutions were minimally toxic after 5 min. Exposure to 3M  
223 concentrations of solutions for 120 min resulted in significant toxicity in a number of  
224 different single-CPA and three-CPA solutions (Figure 2). Similar results to those  
225 presented in Figure 2 were noted from 3M two-CPA solutions (data not shown).

226

227 Figure 1 here

228

229 Figure 2 here

230

231

232 Cell viability was measured using two methods including membrane integrity and  
233 metabolic activity to improve confidence that the cells were indeed viable. Table 1 lists  
234 the cell recovery using these two methods and ranks the different solutions based on cell  
235 viability. It can be seen that cell recovery was similar using these two methods.

236

237 Table 1. Comparison of cell viability using membrane integrity and metabolic assays.

238

3M	Membrane Integrity		Metabolic Activity	
	Rank	Recovery (%)	Rank	Absorbance
EG-Me <sub>2</sub> SO-Gly	1	94	2	1.03
GLYC-GLYC-GLYC	2	92	4	0.98
EG-EG-EG	3	91	1	1.07
Gly-Me <sub>2</sub> SO-Form	4	91	3	1.01
EG-Gly-Form	5	90	5	0.98
EG-PG-Gly	6	87	9	0.84
Gly-PG-Form	7	85	7	0.92
EG-Me <sub>2</sub> SO-Form	8	85	8	0.89
Gly-Me <sub>2</sub> SO-PG	9	82	6	0.94
EG-PG-Form	10	79	10	0.7
EG-Me <sub>2</sub> SO-PG	11	72	11	0.67
Me <sub>2</sub> SO-Me <sub>2</sub> SO-Me <sub>2</sub> SO	12	44	12	0.54
FORM-FORM-FORM	13	43	15	0.36
Me <sub>2</sub> SO-PG-Form	14	33	13	0.46
PG-PG-PG	15	14	14	0.37

239

240

241 To extract the maximum amount of information from this data, a statistical analysis was  
242 performed. Using a linear regression model from all the data demonstrated the toxicity of  
243 individual CPAs to be as follows: PG, Me<sub>2</sub>SO, and Form exhibited greater toxicity than  
244 EG and Gly. This was consistent for all three levels of combinations.

245

246 When considering the data from single-CPA solutions (Table 2), EG and Gly were non-  
247 toxic at these concentrations for these time exposures. PG tended to be more toxic than  
248 Me<sub>2</sub>SO and Form. The data from the two-CPA solutions (Table 3) suggested that all  
249 combinations had a positive effect (i.e. decreased toxicity). In fact, all Me<sub>2</sub>SO  
250 combinations were non-toxic or close to non-toxic. The least significant interactions were  
251 noted when two CPAs from the same set of most toxic (Me<sub>2</sub>SO, PG, Form) or least toxic  
252 (EG, Gly) were mixed. Adding EG or Gly appeared to mitigate toxicity. The rank order  
253 of toxicity was the same in the single- and two-CPA solutions.

254

255 Table 2. Table showing statistical analysis of cell viability results considering solutions  
256 containing only 1 CPA.

257

<b>Considering 1 CPA only</b>			
<u>Sample</u>	<u>Coefficient</u>		<u>Std Dev</u>
Control	1.11		0.06
Me <sub>2</sub> SO	-0.22		0.03
PG	-0.31		0.03
EG	-0.07		0.03
Gly	-0.069		0.03
Form	-0.22		0.03

258

259

260

261

262

263

264

265

266 Table 3. Table showing statistical analysis of cell viability results considering mixtures  
267 containing 2 CPAs.

268

<b>Considering 2 CPAs</b>			
<u>Sample</u>	<u>Coefficient</u>		<u>Std Dev</u>
Control	1.12		0.03
Me <sub>2</sub> SO	-0.25		0.03
PG	-0.31		0.03
EG	-0.09		0.03
Gly	-0.09		0.03
Form	-0.23		0.03
Me <sub>2</sub> SO + PG	0.05		0.03
Me <sub>2</sub> SO + EG	0.08		0.03
Me <sub>2</sub> SO + Gly	0.07		0.03
Me <sub>2</sub> SO + Form	0.05		0.03
PG + EG	0.13		0.03
PG + Gly	0.14		0.03
PG + Form	0.02		0.03
EG + Gly	0.02		0.03
EG + Form	0.08		0.03
Gly + Form	0.11		0.03

269

270

## 271 **Discussion**

272 Development of effective vitrification solutions will require more detailed knowledge  
273 about CPA toxicity with respect to the specific cell types within the tissue being  
274 cryopreserved. There is scant information regarding either toxic effects of currently used  
275 CPAs on articular chondrocytes, or the effects of combining CPAs. This study  
276 demonstrated that toxicity of specific CPAs could be determined and that interactions do  
277 exist between CPAs. Two methods of cell viability were used and they provided very  
278 similar results. The membrane integrity assay was evaluated directly (each cell counted)  
279 while the WST assay was evaluated indirectly (colorimetric assay); therefore, the

280 statistical analysis was performed using the membrane integrity data only. The objectives  
281 of the study were to investigate the rank order of chondrocyte toxicity of each of the five  
282 common CPAs and any interactions that exist between them.

283

284 The raw data from the different CPA solutions (Figures 1 and 2) showed that CPA  
285 solutions of 1M for up to 120 minutes are minimally toxic. As the concentration  
286 increased to 3M and the time increased to 120 minutes, toxicity occurred in a number of  
287 solutions including Me<sub>2</sub>SO, PG, Form, and most combinations containing at least two of  
288 these three CPAs. Surprisingly, EG and Gly showed little toxicity at 3M over this time  
289 period and most of the combinations that included EG and Gly also showed little toxicity.  
290 In fact, EG, Gly and EG-Me<sub>2</sub>SO-Gly solutions were three solutions that did not  
291 demonstrate significant toxicity after 120 minutes. This suggested that solution  
292 combinations containing EG and Gly should be considered for vitrification solutions in  
293 AC cryopreservation. This was consistent with the results in mouse morulae[30] and  
294 shrimp embryo and larvae[29] that demonstrate the least toxicity using EG. Conversely,  
295 other studies in flounder[31], fish germ cells[27], abalone embryos[26] and zebrafish  
296 follicles[25] demonstrated increased toxicity with either EG or Gly. Thus, for porcine  
297 articular chondrocytes, EG and Gly are the least toxic CPAs but these results may not be  
298 applicable to other types of cells.

299

300 The data from single-, and two-CPA solutions consistently demonstrated that PG,  
301 Me<sub>2</sub>SO, and Form induced greater toxicity than EG and Gly. Further ordering was not  
302 possible based on the available data. This result is interesting because Me<sub>2</sub>SO is the most

303 commonly used CPA for many tissues including AC, yet it is not the least toxic. The  
304 common use of Me<sub>2</sub>SO is likely due to historical reasons (one of the first accepted CPAs)  
305 and it is the CPA with the most information about its toxicity and mechanism of action.  
306 Me<sub>2</sub>SO may still be useful as the two-CPA solutions containing Me<sub>2</sub>SO were either non-  
307 toxic or close to non-toxic despite the toxicity of Me<sub>2</sub>SO itself suggesting positive  
308 interactions with other CPAs. This may be the explanation behind the relatively  
309 successful cryopreservation achieved using VS 55, a solution that contains the three most  
310 toxic CPAs (Me<sub>2</sub>SO, PG, and Form)[32]. This also supports Fahy's conclusion that there  
311 is a positive interaction when Me<sub>2</sub>SO is combined with formamide[20; 24].

312

313 Another important finding from this experiment was that adding two CPAs together is  
314 less toxic than one CPA at the same final concentration, irrespective of what CPAs were  
315 used. This can be seen from Table 3 that shows all single CPA solutions exhibit a  
316 negative coefficient while all 2-CPA component solutions have positive coefficients  
317 indicating less toxicity. One difficulty in determining the exact nature of this interaction  
318 was that EG and Gly were not toxic at the concentration and time used, therefore, we can  
319 not conclusively say that adding them to other CPAs is beneficial. It was also shown that  
320 if a more toxic CPA has to be used (e.g. Me<sub>2</sub>SO, PG, or Form), then EG or Gly should be  
321 added to reduce or mitigate that toxicity because these two CPAs have been shown to  
322 have the least toxicity of the five examined and have larger positive coefficients when  
323 combined with more toxic CPAs (Table 3).

324

325 One limitation of this study was that it was performed at a maximum concentration of 3M  
326 due to considerations of osmotic stress when adding each CPA. This study was not  
327 designed to develop a vitrification solution for AC; therefore, these results may not  
328 extrapolate to higher concentrations required for vitrification (approximately 8M). This  
329 experiment did not investigate the mechanism of toxicity, but the end result (viability) of  
330 chondrocyte exposure to CPAs. This experiment was performed using cells removed  
331 from the matrix. It is well documented that cells removed from the matrix do not respond  
332 the same as cells *in situ*; therefore, it is possible that this information is not completely  
333 applicable to cells *in situ*. We performed the experiment in this manner to eliminate  
334 confounding variables such as CPA permeation in the matrix. Finally, the results of this  
335 experiment are likely not applicable to other cell types for the reasons mentioned  
336 previously.

337

338 In conclusion, this is the most comprehensive study investigating CPA toxicity in  
339 chondrocytes. It was determined that EG and Gly were the least toxic CPAs to isolated  
340 porcine articular chondrocytes when used individually. Furthermore, when CPAs are  
341 combined at lower concentrations, there was a positive effect (i.e. less toxicity) when  
342 compared to a single CPA at the same concentration. When adding CPAs together, it is  
343 likely best to make the additional CPA either EG or Gly.

344

345

346 **References**

- 347 [1] S. Gortz, and W.D. Bugbee, Allografts in articular cartilage repair. *J Bone Joint Surg*  
348 *Am* 88, (2006) 1374-84.
- 349 [2] P.P. Aubin, H.K. Cheah, A.M. Davis, and A.E. Gross, Long-term followup of fresh  
350 femoral osteochondral allografts for posttraumatic knee defects. *Clin Orthop*,  
351 (2001) S318-327.
- 352 [3] S.T. Ball, D. Amiel, S.K. Williams, W. Tontz, A.C. Chen, R.L. Sah, and W.D.  
353 Bugbee, The effects of storage on fresh human osteochondral allografts. *Clin*  
354 *Orthop Relat Res*, (2004) 246-52.
- 355 [4] S.K. Williams, D. Amiel, S.T. Ball, R.T. Allen, V.W. Wong, A.C. Chen, R.L. Sah,  
356 and W.D. Bugbee, Prolonged storage effects on the articular cartilage of fresh  
357 human osteochondral allografts. *J Bone Joint Surg Am* 85-A, (2003) 2111-20.
- 358 [5] R.J. Williams, 3rd, J.C. Dreese, and C.T. Chen, Chondrocyte survival and material  
359 properties of hypothermically stored cartilage: an evaluation of tissue used for  
360 osteochondral allograft transplantation. *Am J Sports Med* 32, (2004) 132-9.
- 361 [6] R.S. Rohde, R.K. Studer, and C.R. Chu, Mini-pig fresh osteochondral allografts  
362 deteriorate after 1 week of cold storage. *Clin Orthop Relat Res*, (2004) 226-33.
- 363 [7] T.I. Malinin, W. Mnaymneh, H.K. Lo, and D.K. Hinkle, Cryopreservation of articular  
364 cartilage. Ultrastructural observations and long-term results of experimental distal  
365 femoral transplantation. *Clin Orthop*, (1994) 18-32.
- 366 [8] C. Ohlendorf, W.W. Tomford, and H.J. Mankin, Chondrocyte survival in  
367 cryopreserved osteochondral articular cartilage. *J Orthop Res* 14, (1996) 413-416.
- 368 [9] N.M. Jomha, G. Lavoie, K. Muldrew, N.S. Schachar, and L.E. McGann,  
369 Cryopreservation of intact human articular cartilage. *J Orthop Res* 20, (2002)  
370 1253-5.
- 371 [10] J. Bujia, D. Kremer, H. Sudhoff, E. Viviente, C. Sprekelsen, and E. Wilmes,  
372 Determination of viability of cryopreserved cartilage grafts. *Eur Arch*  
373 *Otorhinolaryngol* 252, (1995) 30-34.
- 374 [11] N.M. Jomha, P.C. Anoop, and L.E. McGann, Intramatrix events during  
375 cryopreservation of porcine articular cartilage using rapid cooling. *J Orthop Res*  
376 22, (2004) 152-7.
- 377 [12] D.E. Pegg, L. Wang, and D. Vaughan, Cryopreservation of articular cartilage. Part 3:  
378 The liquidus-tracking method. *Cryobiology* 52, (2006) 360-368.
- 379 [13] Y. Pichugin, G.M. Fahy, and R. Morin, Cryopreservation of rat hippocampal slices  
380 by vitrification. *Cryobiology* 52, (2006) 228-40.
- 381 [14] N.H. Jutte, P. Heyse, H.G. Jansen, G.J. Bruining, and G.H. Zeilmaker, Vitrification  
382 of human islets of Langerhans. *Cryobiology* 24, (1987) 403-411.
- 383 [15] G.M. Fahy, B. Wowk, J. Wu, J. Phan, C. Rasch, A. Chang, and E. Zendejas,  
384 Cryopreservation of organs by vitrification: perspectives and recent advances.  
385 *Cryobiology* 48, (2004) 157-78.
- 386 [16] E. Elder, Z. Chen, A. Ensley, R. Nerem, K. Brockbank, and Y. Song, Enhanced  
387 tissue strength in cryopreserved, collagen-based blood vessel constructs.  
388 *Transplant Proc* 37, (2005) 4625-9.

389 [17] H.Y. Elmoazzen, A. Poovadan, G.K. Law, J.A. Elliott, L.E. McGann, and N.M.  
390 Jomha, Dimethyl sulfoxide toxicity kinetics in intact articular cartilage. *Cell*  
391 *Tissue Bank* 8, (2007) 125-33.

392 [18] M. Wusteman, U. Rauen, J. Simmonds, N. Hunds, and D.E. Pegg, Reduction of  
393 cryoprotectant toxicity in cells in suspension by use of a sodium-free vehicle  
394 solution. *Cryobiology* 56, (2008) 72-9.

395 [19] A.V. Perruccio, J.D. Power, and E.M. Badley, Revisiting arthritis prevalence  
396 projections--it's more than just the aging of the population. *J Rheumatol* 33,  
397 (2006) 1856-62.

398 [20] G.M. Fahy, B. Wowk, J. Wu, and S. Paynter, Improved vitrification solutions based  
399 on the predictability of vitrification solution toxicity. *Cryobiology* 48, (2004) 22-  
400 35.

401 [21] G.M. Fahy, T.H. Lilley, H. Linsdell, M.S. Douglas, and H.T. Meryman,  
402 Cryoprotectant toxicity and cryoprotectant toxicity reduction: in search of  
403 molecular mechanisms. *Cryobiology* 27, (1990) 247-68.

404 [22] S.J. Baxter, and G.H. Lathe, Biochemical effects of kidney of exposure to high  
405 concentrations of dimethyl sulphoxide. *Biochem Pharmacol* 20, (1971) 1079-  
406 1091.

407 [23] T. Arakawa, J.F. Carpenter, Y.A. Kita, and J.H. Crowe, The basis for toxicity of  
408 certain cryoprotectants: A hypothesis. *Cryobiology* 27, (1990) 401-415.

409 [24] G.M. Fahy, Cryoprotectant toxicity neutralization. *Cryobiology*, (2009).

410 [25] S. Tsai, D.M. Rawson, and T. Zhang, Studies on cryoprotectant toxicity to early  
411 stage zebrafish (*Danio rerio*) ovarian follicles. *Cryo Letters* 29, (2008) 477-83.

412 [26] A. Roux, L. Sandenbergh, and R. Roodt-Wilding, Preliminary investigation to  
413 determine the cytotoxicity of various cryoprotectants on southern African abalone  
414 (*Haliotis midae*) embryos. *Cryobiology* 57, (2008) 308-11.

415 [27] M. Plachinta, T. Zhang, and D.M. Rawson, Studies on cryoprotectant toxicity to  
416 zebrafish (*Danio rerio*) oocytes. *Cryo Letters* 25, (2004) 415-24.

417 [28] M.C. Wusteman, D.E. Pegg, M.P. Robinson, L.H. Wang, and P. Fitch, Vitrification  
418 media: toxicity, permeability, and dielectric properties. *Cryobiology* 44, (2002)  
419 24-37.

420 [29] Q.X. Dong, J.D. Lin, and C.J. Huang, Effects of cryoprotectant toxicity on the  
421 embryos and larvae of pacific white shrimp *Litopenaeus vannamei*. *Aquaculture*  
422 242, (2004) 655-670.

423 [30] J. Ali, and J.N. Shelton, Design of vitrification solutions for the cryopreservation of  
424 embryos. *J Reprod Fertil* 99, (1993) 471-7.

425 [31] Y.Z. Zhang, S.C. Zhang, X.Z. Liu, Y.J. Xu, J.H. Hu, Y.Y. Xu, J. Li, and S.L. Chen,  
426 Toxicity and protective efficiency of cryoprotectants to flounder (*Paralichthys*  
427 *olivaceus*) embryos. *Theriogenology* 63, (2005) 763-73.

428 [32] J. Guan, J.P. Urban, Z.H. Li, D.J. Ferguson, C.Y. Gong, and Z.F. Cui, Effects of  
429 rapid cooling on articular cartilage. *Cryobiology* 52, (2006) 430-439.

430  
431  
432

433 Figure Captions

434

435 Figure 1 Title. 1M Toxicity at 37°C

436

437 Figure 1. Cell recovery after exposure to 1M (single and three-CPA) solutions for 5 min  
438 and 120 min as determined by membrane integrity stains..The controls are absolute  
439 values while the experimental solutions have been normalized to their own internal  
440 controls taken from the same tissue. The negative control of 100% Me<sub>2</sub>SO at the right of  
441 the x axis and had 0% recovery. There was minimal difference between any solution.

442

443 Figure 2 Title. 3M Toxicity at 37°C

444

445 Figure 2. Cell recovery after exposure to 3M (single and three-CPA) solutions for 5 min  
446 and 120 min as determined by membrane integrity assays. The solutions are listed in  
447 order of descending recovery after 120 min. The controls are absolute values while the  
448 experimental solutions have been normalized to their own internal controls taken from  
449 the same tissue. The three-CPA solution containing EG-Me<sub>2</sub>SO-Gly resulted in the  
450 highest cell viability. The single-CPA solutions of Gly and EG also had the highest  
451 viability. The negative control of 100% Me<sub>2</sub>SO is at the right side of the x axis and had  
452 0% recovery.

453